These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 4652593)

  • 1. New platinum complexes with anti-tumour activity.
    Connors TA; Jones M; Ross WC; Braddock PD; Khokhar AR; Tobe ML
    Chem Biol Interact; 1972 Nov; 5(6):415-24. PubMed ID: 4652593
    [No Abstract]   [Full Text] [Related]  

  • 2. Platinum complexes: a new class of antineoplastic agents.
    Leh FK; Wolf W
    J Pharm Sci; 1976 Mar; 65(3):315-28. PubMed ID: 1263076
    [No Abstract]   [Full Text] [Related]  

  • 3. Studies on the mechanism of action of the tumour inhibitory triazenes.
    Audette RC; Connors TA; Mandel HG; Merai K; Ross WC
    Biochem Pharmacol; 1973 Aug; 22(15):1855-64. PubMed ID: 4722457
    [No Abstract]   [Full Text] [Related]  

  • 4. Structure and activity relationships of platinum complexes with anti-tumour activity.
    Braddock PD; Connors TA; Jones M; Khokhar AR; Melzack DH; Tobe ML
    Chem Biol Interact; 1975 Sep; 11(3):145-61. PubMed ID: 1157188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes.
    Kelland LR; Barnard CF; Evans IG; Murrer BA; Theobald BR; Wyer SB; Goddard PM; Jones M; Valenti M; Bryant A
    J Med Chem; 1995 Aug; 38(16):3016-24. PubMed ID: 7636864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New tumor-inhibiting metal complexes.
    Keppler BK; Berger MR; Heim ME
    Cancer Treat Rev; 1990 Sep; 17(2-3):261-77. PubMed ID: 2272042
    [No Abstract]   [Full Text] [Related]  

  • 7. [Cytostatic non-platinum metal complexes: new perspectives for the treatment of cancer?].
    Köpf-Maier P
    Naturwissenschaften; 1987 Aug; 74(8):374-82. PubMed ID: 3309682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effects of rhodium(I), iridium(I) and ruthenium(II) complexes in comparison with cis-dichlorodiammino platinum(II) in mice bearing Lewis lung carcinoma.
    Sava G; Giraldi T; Mestroni G; Zassinovich G
    Chem Biol Interact; 1983 Jul; 45(1):1-6. PubMed ID: 6683595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of antitumor platinum compounds with trans geometry on the induction of cytotoxicity and cell cycle modifications.
    Barletta A; Coluccia M; Nassi A; Pardiso A
    Eur J Histochem; 1997; 41 Suppl 2():61-2. PubMed ID: 9859784
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-tumour activity of heavy transition metal complexes against hepatoma cells.
    Dehand J; Jordanov J
    Chem Biol Interact; 1975 Dec; 11(6):605-9. PubMed ID: 172246
    [No Abstract]   [Full Text] [Related]  

  • 11. [Antineoplastic activity of complex compounds of platinum(IV)].
    Presnov MA; Zheligovskaia NN; Babkov AV; Konovalova AL; Budanova NS
    Dokl Akad Nauk SSSR; 1976 JUL-AUG; 229(1):226-9. PubMed ID: 954573
    [No Abstract]   [Full Text] [Related]  

  • 12. [Antineoplastic properties of complex compounds of platinum(II)].
    Presnov MA; Konovalova AL; Stetsenko AI; Ivanov VF; Iakovlev KI
    Dokl Akad Nauk SSSR; 1976 Oct; 230(6):1357-9. PubMed ID: 976058
    [No Abstract]   [Full Text] [Related]  

  • 13. Antineoplastic activity and toxicity of an organometallic complex of ruthenium(II) in comparison with cis-PDD in mice bearing solid malignant neoplasms.
    Sava G; Zorzet S; Giraldi T; Mestroni G; Zassinovich G
    Eur J Cancer Clin Oncol; 1984 Jun; 20(6):841-7. PubMed ID: 6540184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemotherapy of advanced murine myeloma and subsequent resistance to tumor cell challenge.
    Teller MN; Bowie M; Mountain IM; Stock CC
    J Natl Cancer Inst; 1974 Mar; 52(3):667-71. PubMed ID: 4857022
    [No Abstract]   [Full Text] [Related]  

  • 15. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the preclinical activity of budotitane in three different transplantable tumor systems, its lack of mutagenicity, and first results of clinical phase I studies.
    Keppler BK; Heim ME; Flechtner H; Wingen F; Pool BL
    Arzneimittelforschung; 1989 Jun; 39(6):706-9. PubMed ID: 2775338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of metallocenic drugs.
    Engel J; Schumacher W; Schönenberger H
    IARC Sci Publ; 1986; (78):295-307. PubMed ID: 3583395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumour properties of dimethylsulphoxide ruthenium (II) complexes in the Lewis lung carcinoma system.
    Sava G; Pacor S; Zorzet S; Alessio E; Mestroni G
    Pharmacol Res; 1989; 21(5):617-28. PubMed ID: 2594617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Water-soluble organometallic analogues of oxaliplatin with cytotoxic and anticlonogenic activity.
    Benedetti M; Antonucci D; Migoni D; Vecchio VM; Ducani C; Fanizzi FP
    ChemMedChem; 2010 Jan; 5(1):46-51. PubMed ID: 19950163
    [No Abstract]   [Full Text] [Related]  

  • 20. Growth characteristics of MOPC-315 plasmacytoma and response to anticancer agents.
    Valeriote F; Lynch R; Berger NA; White E; Coulter D
    J Natl Cancer Inst; 1981 Jun; 66(6):1083-8. PubMed ID: 7017213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.